drugset / Trial / NCT05707351

A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

NCT05707351

Phase 3 Completed 37 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The main aim of the study is to determine how well Adynovate works to decrease bleeding in previously treated Chinese men and boys with severe hemophilia A when given prophylactically. Participants will be treated with Adynovate twice a week for 26 weeks or until participants have received 50 days of treatment with Adynovate (whichever takes longer). Participants will need to visit their study clinic several times during their participation.

Timeline

Start
2023-03-27
Primary completion
2024-09-05
Completion
2024-09-05

Drugs

EvaluationDrugModalityDoseRoute
Subject ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT Protein / enzyme biologic 45 iu/kg Intravenous

Indications